What lessons have been learnt from animal models of MRSA in the lung?
Staphylococcus aureus is one of the most common causes of nosocomial pneumonia contributing to significant morbidity and mortality. Therapeutic options for patients with methicillin-resistant S. aureus (MRSA) infection are limited. In addition, little is known about the S. aureus virulence factors that may influence the presentation and prognosis of severe lower respiratory tract infections. Animal models of severe pneumonia allow investigators to control and exclude potential confounders and to examine the influence of comorbid conditions. Therefore, these models may improve our knowledge of the intimate pathophysiological mechanisms affecting pharmacodynamics, pharmacokinetics and efficacy of therapy. So far, animal research studies on MRSA and vancomycin-resistant S. aureus, performed both in small and large animal models, have improved knowledge of the mechanisms of disease, which may lead to a better treatment for this severe and complex infection in humans.